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Abstract 
Haemostasis is a complex process that ensures the maintenance of blood flow under normal 
physiological conditions and prevents major blood loss following vascular injury. The process is tightly 
regulated to prevent pathological thrombosis. Normal haemostasis relies on the delicate balance of 
prothrombotic and anticoagulant processes, where five components play a significant role in 
maintaining the haemostasis, these include: 1) endothelial cells; 2) Platelets which are key to platelet 
plug formation; 3) coagulation factors that are essential to formation of insoluble fibrin clot; 4) 
coagulation inhibitors; and 5) fibrinolysis  
This article will provide an overview of the current concepts of haemostasis, and through this we will 
explain how antiplatelets and antithrombotic drugs work, as well as provide a basic understanding of 
how to interpret clotting tests used to measure coagulation disorders.  
Keywords: Coagulation, Haemostasis, Platelets, Bleeding, Haemorrhage, Anticoagulants, antiplatelets, 
clotting tests 
Royal College of Anaesthetists CPD Matrix : 1A01: Physiology and biochemistry, 1A02: Pharmacology 
and therapeutics 
 
Learning Objectives 
After reading this article, you should be able to:  
1) Identify the key components of haemostasis  
2) Describe the principles of how some major inherited bleeding disorders impact haemostasis 
3) Interpret abnormal coagulation assays  
4) Describe how antiplatelets and anticoagulants affect coagulation.  
 
 
Introduction 
 
The haemostatic pathway is a tightly regulated process that ensures the maintenance of blood flow 
under normal physiological conditions and also facilitates the prevention of significant blood loss 
following vascular injury. The normal haemostatic response depends on the closely linked interaction 
between a) blood vessel wall (endothelial cells), b) platelets, and c) blood coagulation factors. Whilst an 
efficient and rapid mechanism for stopping bleeding is essential for survival, it is equally important that 
this mechanism is tightly controlled, so that pathological thrombosis is prevented. Therefore, normal 
haemostasis relies on the delicate balance of prothrombotic and anticoagulant processes.  
There are five Components of Haemostasis  
1) Blood vessels and endothelial cells 
2) Platelets  
3) Coagulation factors  
4) Coagulation inhibitors  
5) Clot dissolution or Fibrinolysis  
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This article will provide an overview of the current concepts of haemostasis, and through this we will 
explain how antiplatelets and antithrombotic drugs work, and also provide a basic understanding of how 
to interpret clotting tests used to measure coagulation disorders.  
 
Blood Vessels and Endothelial Cells  
Following vascular injury, vessel walls vasoconstrict immediately to slow blood flow to the site of injury 
as well as prevent exsanguination from widespread damage.(4) In addition, collagen and tissue factor (TF) 
are brought into contact with flowing blood. Exposed collagen triggers the accumulation and activation 
of platelets at the site of the vessel wall damage resulting in the formation of a platelet plug, while the 
exposed TF initiates the activation of coagulation factors and generation of thrombin which in turn will 
lead to formation and stabilisation of insoluble fibrin clot. 
 
Platelet Structure and Function 
Platelets are anucleate, extremely small, discoid cells which circulate in abundant numbers in the 
peripheral blood.  They are formed by fragmentation from megakaryocytes within the bone marrow and 
have a lifespan of 7-10 days. Platelets are essential in the initial formation of a mechanical plug in 
response to vessel injury and they achieve this through four main functions: 1) activation; 2) adhesion to 
the vessel wall; 3) aggregation; and 4) secretion. Activated platelets provide a surface for activation and 
recruitment of more platelets, as well as activation of coagulation factors, which will ultimately will lead 
to fibrin formation.  
Platelet Membrane: the platelet membrane invaginates into the interior of the cell and forms an 
extensive canalicular system, which provides a large area of numerous membrane receptors and 
proteins.  Of particular importance in the platelet membrane are phospholipids which activate 
coagulation factors such as factor X (FX) and Factor II (prothrombin). Surface receptors activate 
intracellular pathways which lead to a conformational change in platelet structure and shape upon 
activation. The membrane also contains numerous glycoproteins which serve as binding sites for various 
other molecules such as Von Willebrand factor (vWF), Fibrinogen (adhesion) as well as binding to other 
platelets (aggregation). Table 1 summaries the roles and clinical significance of some of the platelet 
membrane proteins.(3)  
Storage granules: Two important intracellular components within platelets are alpha and dense storage 
granules: 
 α granules-contain P-selectin, fibrinogen, fibronectin, factor V, factor VIII, platelet factor IV, 
platelet-derived growth factor and tumour growth factor-α (TGF-α) 
 dense granules-contain adenosine triphosphate (ATP), adenosine diphosphate (ADP), calcium 
(Ca), serotonin, histamine and epinephrine.9  
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Platelet Activation 
There are numerous agonists of platelet activation such as ADP, collagen serotonin – all these lead to 
activation of intracellular pathways. Collagen a potent activator of platelets, is  released from vessel 
endothelium and  binds to Glycoprotein (GP) 1a and GPVI, which activates the cyclooxygenase (COX) 
system that will generate thromboxane A2 (TXA2). TXA2 has several haemostatic functions, such as: it 
causes vasoconstriction, it leads to recruitment and further activation of more platelets via 
thromboxane surface membrane receptors, and also causes platelet aggregation. Aspirin inhibits TXA2 
production by irreversible inhibition of COX enzyme (Table 2). 
 
Platelet Adhesion 
Upon activation, platelets undergo considerable conformational change in order to maximize surface 
area for adhesion to other surfaces. vWF is essential in promoting platelet adhesion in high shear 
conditions.  vWF is released from the vascular endothelium where it is continually secreted and is stored 
within platelet granules and in Weibel-Palade bodies within endothelial cells. vWF is a large multimeric 
molecule that is essential in platelet adhesion, aggregation, and also act as a carrier for coagulation FVIII. 
Dysfunctional, or deficiency of VWF results in a bleeding diathesis. Shear forces, stress, exercise, 
adrenaline and Desmopressin/DDAVP stimulates the release of vWF and thus will raise its plasma levels. 
DDAVP has therapeutic benefit in functional platelet disorders and in Von Willebrand disease.  
 
Platelet Aggregation 
Platelet aggregation is achieved by platelets cross linking at GPIIb/IIIa receptors on the platelet 
membrane. GPIIb/IIIa is the most abundant glycoprotein, and upon activation it undergoes 
conformational change allowing it to bind to fibrinogen, thus forming platelet-fibrinogen bridges. ADP, 
TXA1 and thrombin all activate GPIIb/IIIa and are potent enhancers of platelet aggregation.  
 
Platelet Secretion 
Once activated, platelets release procoagulant substances that are responsible for a ‘secondary wave’ of 
aggregation after the initial activation of platelets. The two most significant substances responsible for 
this positive feedback are ADP (released from dense granules), and TXA2 generated from COX pathway. 
Other substances released from granules include serotonin, Fibrinogen, Fibronectin, and growth factors 
such as PDGF. Impaired release of these mediators results in qualitative defects of platelet function 
which can be both congenital or acquired (e.g. drug induced). Antiplatelet therapies target various 
pathways of platelet activation and aggregation - their target, route of administration and their half-lives 
are described in Table 2.  
After activation, aggregation and secretion, the membrane phospholipid becomes exposed resulting in 
activation of the clotting cascade. Platelet phospholipids are essential for activation of FX and FII 
(thrombin) and the formation of the tenase (Factors Xa-VIIIa- IXa) and prothombinase complexes (Xa-Va-
IIa).  
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Coagulation pathway 
The coagulation cascade involves the marked amplification of procoagulant proteins from relatively few 
initiation substances by the sequential activation of enzyme precursors (zymogens) to active enzymes. 
These are usually serine protease enzymes.  The result is the rapid and marked generation of thrombin, 
which converts soluble fibrinogen into the insoluble fibrin. Fibrin enmeshes platelet aggregates and 
converts the unstable platelet plug into a stable fibrin clot.  
Traditionally the coagulation pathway was classified into extrinsic, intrinsic and common pathways. This 
classical model still remains useful in interpreting in vitro coagulation screening tests (i.e. prothrombin 
time [PT], activated partial thromboplastin time [APTT]), however, the classical model does not 
incorporate the central role that cell surfaces play in coagulation. Further, this system does not explain 
why some patients with coagulation factor deficiencies have bleeding tendencies (for example why 
individuals with factor IX or factor VIII deficiency have severe bleeding even though their extrinsic and 
common pathways are normal which should be sufficient for haemostasis)  and more importantly, it 
does not predict which patients are at risk of bleeding or thrombosis.    
 
The Cell Based Model of Haemostasis 
The ‘cell based’ model of haemostasis has replaced the classical pathway and it is now the most widely 
accepted model of in vivo coagulation.  The cell-based model proposes that the coagulation process 
takes place on different cell surfaces and, occurs not as a cascade but in 3 overlapping stages which 
include: 1) initiation, 2) amplification, and 3) propagation.(5,6)   
Initiation  
The primary event of in vivo coagulation is the exposure of tissue factor (TF) which will lead to activation 
of FVII in flowing blood after vascular injury. The TF:FVIIa complex catalyses the activation of FIX and FX. 
The activated FX which escapes the cell surface environment is rapidly inhibited by tissue factor pathway 
inhibitor (TFPI) and antithrombin (AT), whereas that which remains on the TF bearing cell will activate a 
tiny amount of thrombin from prothrombin. This initial thrombin is essential for the activation of more 
platelets, as well as activation of FVIII and FV, thus setting the scene for the large-scale thrombin 
generation. The small initial thrombin generated will also activate factor XI in a positive feedback 
manner, leading to amplification  
 
Amplification  
Platelets provide the surface on which the amplification and propagation phases take place. During the 
amplification phase the procoagulant signal shifts from TF-bearing cells to the surface of platelets as 
these become activated, whilst in the propagation phase, a large burst of thrombin is generated on the 
surface of activated platelets (Figure 1). 
The interaction of platelet GPVI receptor with exposed collagen from the vessel wall damage and 
platelet GP Ib-V-IX receptor with collagen-bound von Willebrand factor (VWF) promotes adhesion of 
platelets to the site of injury. These binding processes partially activate platelets and localize them near 
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the site of TF exposure. Moreover, binding of VWF to GP-Ib-V-IX receptor, 6 localizes FVIII to the surface 
of platelets where its activation will support the thrombin generation process  
Independently, the small amount of thrombin formed during the initiation phase enhances platelet 
adhesion and fully activates platelets as well as FV, FVIII, and FXI. Thrombin induces platelet activation 
by binding to protease-activated-receptor 4 (PAR4) on the platelet surface which in turn causes the 
release of adenosine diphosphate, serotonin and thromboxane A2 from platelets. These agonists 
activate other platelets and in so doing they release FV from α granules. FV is then fully activated by 
thrombin or FXa.  
Propagation  
During the propagation phase, FVIIIa combines with FIXa (generated by TF:VIIa complexes) to form the 
intrinsic ‘tenase’ complexes on the surface of activated platelets. This complex (FVIIIa/FIXa) is a 
powerful and a major activator of FX (10 fold  more active than FIXa alone). FXa in combination with its 
co-factor FVa (and calcium ions) forms ‘prothrombinase’ complexes which will subsequently catalyse 
prothrombin to thrombin. This complex is 300,000-fold more active than FXa alone in catalysing 
prothrombin activation. 
 
Coagulation inhibitors  
It is fundamental that clot formation is regulated and localized to the site of injury, so that arterial or 
venous thrombosis are prevented. Hence, a crucial element to a balanced haemostasis is played by the 
naturally occurring inhibitors to coagulation, which include Tissue factor Pathway Inhibitor (TFPI), 
heparin co-factor II, antithrombin (AT) and protein C and protein S activation . 
TFPI is the principle regulator of the thrombin generation initiation phase (i.e. inhibits FXa , FVIIa and 
TF), whereas AT attenuates thrombin activity and its generation (inhibits FIIa, FXa, FIXa, and FXIa). TFPI is 
synthesized in endothelial cells and is mostly stored in platelets. A small amount is in free circulation in 
the plasma. Plasma concentrations of TFPI are greatly increased with heparin. Heparins bind to 
antithrombin and potentiates its action by 1000-4000 fold.  
Protein C and Protein S are both serine protease enzymes, whose activation is essential for inhibition of 
FVa and FVIIIa. Protein C/S pathway is activated by thrombin which  binds to thrombomodulin (an 
endothelial cell surface receptor),  and activate protein C - this in turn will inactivate FVa and FVIIIa. 
Protein S is a cofactor to activated protein C (APC), potentiating its action.  
Almost all currently available anticoagulant drugs will inhibit either FXa or FIIa (thrombin) – Figure 1 
gives and overview of the Cell based model of haemostasis and the common targets of anticoagulant 
agents.  
 
Fibrinolysis   
Following haemostasis, in order for vessel patency and blood flow to resume, the fibrin clot must be 
removed by proteolytic enzymes. Fibrinolysis is triggered in response to vessel injury, and requires 
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activation of plasminogen to plasmin by the tissue-type plasminogen activator (t-PA) and urokinase-type 
plasminogen activator (u-PA).  
t-PA is stored in the endothelium and is released following endothelial damage or stimulation by 
thrombin or vasoactive agents (adrenaline, bradykinin etc.). Fibrin acts as a cofactor for t-PA to enhance 
the activation of plasminogen. Both TPA and u-Pa are used in clinical practice for thrombolysis – TPA has 
been manufactured in recombinant form and urokinase isolated from human urine. Streptokinase is a 
peptide isolated from haemolytic streptococci which converts plasminogen to plasmin.  
The main regulators of fibrinolytic systems are: plasminogen activator inhibitor-1 (PAI-1) which 
targets u-PA and t-PA; and 2-antiplasmin that targets plasmin. Deficiencies of PAI or alpha-2- 
antiplasmin are rare disorders which result in a severe bleeding diathesis due to uninhibited fibrinolysis. 
The antifibrinolytic drug Tranexamic acid is a synthetic analog of Lysine - which reversibly binds to 
plasminogen and prevents its activation to plasmin. This therefore prevents plasmin from degrading 
fibrin.  
Standard clotting Tests and their interpretation   
The most commonly used clotting assays include prothrombin time (PT), activated partial 
thromboplastin time (APTT), thrombin time (TT) and Clauss fibrinogen assay. All these tests have 
limitations in that they are performed in plasma, and thus they do not reflect the in vivo haemostasis. As 
such, it is important to emphasize that when interpreting their results, the assessment of patient’s 
bleeding history (i.e. current bleeding symptoms, prior bleeding events in responses to haemostatic 
challenges, such as surgery or dental extraction), drug history (use of anticoagulant/antiplatelet drugs), 
and family history of bleeding disorder must be taken into account.   
Prothrombin Time  
The PT measures the time taken for clot formation when TF (thromboplastin) and calcium are added to 
platelet depleted plasma. There are several thromboplastin reagents commercially available, and each 
of them have a variable sensitivity. Hence, in order to standardize the PT assay, individual 
thromboplastin reagents are compared with a World Health Organization standard reference and 
assigned an ISI (International Standardised Index). The ISI of each PT reagent is then used to calculate 
the international normalized ratio (INR – see formula below), which is essential for determining the 
anticoagulant status of patients taking vitamin K antagonist agents (such as warfarin) 
INR is calculated from the following formula:  
INR =  [𝑻𝒆𝒔𝒕 𝑷𝑻 ÷ 𝑹𝒆𝒇𝒆𝒓𝒆𝒏𝒄𝒆 𝑷𝑻 (𝑴𝒆𝒂𝒏 𝒐𝒇 𝟐𝟎 𝒏𝒐𝒓𝒎𝒂𝒍 𝑫𝒐𝒏𝒐𝒓𝒔)] ISI               
PT measures the activity of extrinsic and common pathway, and therefore will be affected by plasma 
concentration of FVII, FV, FX, FII (prothrombin) and fibrinogen.  
 
Activated Partial Thromboplastin Time  
The APTT Measures the activity of the intrinsic pathway, thus it will be affected by abnormalities of 
factors XII, XI, VIII, IX as well as the common pathway factors V, X. II (prothrombin) and fibrinogen.  
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APTT measures the time taken for clot formation in platelet poor plasma after the addition of 
phospholipid (partial thromboplastin), a contact activator (a negatively charged substance that will 
activate the contact system) and calcium. It is important to note that deficiency of FXII (or contact 
factor) will cause marked prolongation of the APTT, but this condition does not carry any bleeding risk.   
Another common pitfall to be aware of when APPTT is prolonged, are the lupus anticoagulant 
antibodies, which are inhibitory antibodies associated with the Antiphopholipid Syndrome (rarely can 
affect the PT). Lupus anticoagulant antibodies are associated with thrombotic tendency rather than 
bleeding risk.(7,8)  
Thrombin Time  
The Thrombin time assesses the conversion of fibrinogen to fibrin and is measured simply by adding 
exogenous thrombin to platelet depleted plasma.  
Fibrinogen Level  
Fibrinogen levels are a useful part of the investigation of prolonged APTT or PT. There are different 
methods of assaying fibrinogen – the two commonest methods are either Clauss Fibrinogen – a 
functional assay based on the time for a fibrin clot formation and the PT derived fibrinogen – where 
fibrinogen level is derived based upon the prothrombin time.  
Clinical interpretation of abnormal clotting tests are described in the Table 3.  
Table 4 provides a summary of anticoagulant drugs, their mechanism of action, effect on coagulation 
tests and haemostatic measures to consider in management of major bleeding.  
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Figures  
Figure 1 –Cell based model of Coagulation Pathway  with targets of common anticoagulants 
highlighted 
 
 
TF: Tissue Factor, UFH: Unfractionated Heparin, LMWH: Low molecular Weight Heparin, VIII, IX, X, XI : 
Coagulation factors VIII, IX, X and XI respectively.  
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Tables 
Table 1 – Role and clinical significance of Key Platelet membrane Proteins 
Membrane Protein  Role  Clinical Significance  
GP1a Binds Collagen  
Activated intracellular pathways 
leading to thromboxane A2 (TXA2) 
generation 
Aspirin suppresses TXA2 synthesis by 
inhibiting COX 
GP1b Binds Von Willebrand Factor  Defective in Bernard Soulier disease  
GPVI Binds Collagen  GP VI Absence results in severe bleeding 
diathesis  
GPIIb/IIIa Binds Fibrinogen and  
Von Willebrand Factor  
Binding site for other platelets in 
aggregation  
Defective in Glanzmanns 
Thrombaesthenia  
 
 
Membrane 
Phospholipid 
Activates coagulation factors Activates  Factor X→ Xa  and Factor II →  
IIa  
P2Y12 Activated by ADP, leads to 
generation of TXA2 and aggregation.  
P2Y12 Inhibited by Clopidogrel and 
Ticagrelor 
 
Key: GP = Glycoprotein, TXA2 = Thromboxane A2, COX= cyclooxygenase, ADP= Adenosine 
Triphospate, P2Y12 = Platlelet Membrane  Protein Receptor 
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Table 2: Summary of antiplatelet drugs, mechanism of action and their limitations  
Drug Target  Binding Route Half Life  
Aspirin 
Acetylates Ser529 of 
COX-1 
Irreversible PO 15–20 minutes 
Ticlopidine ADP-P2Y
12
 Irreversible PO 
20–50hours after a 
single dose 
Clopidogrel ADP P2Y
12
 Irreversible PO 7-8 hours 
Prasugrel ADP P2Y
12
 Irreversible PO 7 hours 
Cangrelor ADP P2Y
12
  Reversible IV 3–5 minutes 
Ticagrelor ADP P2Y
12
 Reversible PO 
7 hours (ticagrelor) 
9 hours (active 
metabolite) 
Abciximab GP IIb/IIIa Irreversible IV 10- 30 minutes 
Tirofiban GP IIb/IIIa Reversible IV 1.5–3 hours 
Eptifibatide GP IIb/IIIa Reversible IV 2 - 3 hours 
Adapted from Laboratory Hematology Practice – Kandice Kottke-Marchat, Bruce Davis, Chapter 41 
Anticoagulant, Antiplatelt and thrombolytic drugs  Wiley –Blackwell 2012 – L Green, S Machin (10) 
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Table 3 – Screening Tests of Coagulation and their Clinical Implication   
Test Principle  Clinical Implication  
APTT  Measure of Intrinsic 
Pathway coagulation 
Factors 
Isolated prolonged APTT: 
Deficiency of FXII, XI, IX, VIII 
Lupus Anticoagulant antibodies 
Antibodies to FVIII or FIX (i.e. acquired 
haemophilia) 
 
Prolonged APTT + PT: 
Vitamin K antagonists (e.g, warfarin)  
Disseminated Intravascular Coagulpathy (DIC)   
Common Pathway Deficiency  
Afibrinogenaemia and dysfibrinogenemia 
Direct Thrombin Inhibitors  
Malabsorption (leading to vitamin K deficiency) 
High concentrations of unfractionated heparin 
Dilutional coagulopathy e.g. massive blood 
transfusion 
 
PT  Measures extrinisic 
and common 
pathway Activity  
Isolated Prolonged PT:  
Deficiency of Factor VII  
Thrombin Time  Time to firbrin clot 
after addition of 
thrombin 
Prolonged Thrombin Time:  
Hypofirbinogenaemia – eg acquired from DIC, 
Malignancy 
Liver disease   
Following thrombolysis  
Congenital  deficiencies of fibrinogen  
Direct Thrombin inhibitors (eg dabigatran) 
 
Fibrinogen  Assay can be 
functional or 
quantitative  
Reduced  
DIC 
Liver disease 
Inherited deficiency of fibrinogen  
Thrombolysis  
 
Increased  
Pregnancy 
Female sex 
Acute phase response,  
 
 
    13 
 
Table 4:  Summary of anticoagulant drugs, their mechanism of action, effect on coagulation tests and haemostatic measures to 
consider in management of major bleeding  
Anticoagulant 
Class 
Examples Route Half-life Mechanism of action Effect on 
Clotting Tests 
Specific assays Reversal agents to consider in 
major bleeding 
Vitamin K 
Antagonist 
(VKAs) 
Warfarin 
Sinthrome 
Coumadin 
PO 40-70 hrs Vitamin K Epoxide Reductase 
inhibition – Factors II, VII, IX, X, 
protein C, S, Z 
PT ↑↑↑ 
APTT ↑↑ 
Fib ↔ 
TT↔/ ↑ 
INR  Vitamin K 
Prothrombin Complex Concentrate 
(PCC) 
Unfractionated 
Heparin 
Unfractionated 
Heparin 
IV  30 mins- 
4h 
Potentiation of Antithrombin - 
Targets IIa, Xa, IXa, XIa 
 
PT ↔/ ↑ 
APTT ↑↑↑ 
Fib ↔ 
TT ↔/ ↑ 
APTT ratio Protamine 
 
Low Molecular 
Weight Heparin 
Enoxaparin 
Dalteparin 
Tinzaparin 
SC 
SC 
SC 
3 – 6 hrs Potentiation of Antithrombin -  
targets Xa, IIa, Tissue factor 
pathway inhibitor 
PT ↔/ ↑ 
APTT ↑↑ 
Fib ↔ 
TT↔/ ↑ 
*Anti Xa Level 
using 
respective 
LMWH  
Consider Protamine if  <16 hr of 
administration 
 
Indirect Xa 
Inhibitor 
Fondaparinux SC 17-20 hrs Target Xa inhibition, through 
potentiation of Antithrombin 
PT↔/ ↑↑ 
APTT ↔/↑ 
Fib ↔ 
TT↔ 
*Anti Xa Level 
using 
fondaparinux 
No antidote 
Consider Tranexamic acid + PCC in 
severe bleeding 
Direct Xa 
inhibitors 
Apixaban 
Rivaroxaban 
Edoxaban 
 
 
PO BD 
PO OD 
PO OD 
 
8-15 hrs 
5- 13 hrs 
10-14 rs 
Direct Xa Inhibition PT ↔/ ↑↑ 
APTT ↔/↑ 
Fib ↔ 
TT↔ 
*Anti Xa Level 
using 
respective 
drugs 
No reversal agent yet available  
(Andexanat Alpha awaiting licence) 
 
Tranexamic acid 
Consider PCC in severe bleeding 
Direct 
Thrombin 
Inhibitors 
Dabigatran 
Argartroban 
Bivalrirudin 
Hirudin 
PO BD 
IV 
IV  
IV 
12–17hrs 
45 min 
25 min 
1-2 hrs 
Direct Thrombin Inhibition PT ↑/ 
APTT ↑↑ 
Fib ↑ 
TT ↑↑↑↑↑ 
*Haemoclot 
Assay or dilute 
thrombin time  
Idaricizumab if available 
No antidote for parenteral Direct 
Thrombin inhibitors 
*Monitoring not required. 
The effect of anticoagulants may cause prolongation of a single or multiple clotting tests but can do so to a varying degree or not at all. Clotting tests 
highlighted in bold show the clotting test that would be expected to be most significantly prolonged due to the anticoagulant.  Key: ↑ = Prolongation 
(quantitative), ↑↑= Moderate Prolongation ↑↑↑ = Marked Prolongation,  ↔ = Unchanged. LMWH= Low Molecular weight heparin, PT = prothrombin time 
APTT= Activated partial thromboplastin time, Fib= fibrinogen, TT = Thrombin time
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